The estimated Net Worth of Michael Weiser is at least $1.86 Milhão dollars as of 31 May 2022. Michael Weiser owns over 10,000 units of Iovance Biotherapeutics Inc stock worth over $1,053,109 and over the last 19 years he sold IOVA stock worth over $97,950. In addition, he makes $708,375 as Independent Director at Iovance Biotherapeutics Inc.
Sign up
Michael Weiser IOVA stock SEC Form 4 insiders trading
Michael has made over 6 trades of the Iovance Biotherapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of IOVA stock worth $68,000 on 31 May 2022.
The largest trade he's ever made was exercising 20,000 units of Iovance Biotherapeutics Inc stock on 8 December 2017 worth over $54,600. On average, Michael trades about 2,571 units every 115 days since 2006. As of 31 May 2022 he still owns at least 112,632 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Michael Weiser stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Weiser biography
Dr. Michael Weiser M.D. Ph.D. serves as Independent Director of the Company. Dr. Weiser joined our Board of Directors in March 2018. He is the founder and has been a principal of Actin Biomed LLC since 2006. Actin Biomed is a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm. Dr. Weiser currently serves on the board of directors of Emisphere Technologies, Inc., a pharmaceutical and drug delivery company. Dr. Weiser previously served as the chairman of the board of directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014, and served on the board of directors of Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received his M.D. from New York University School of Medicine and completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College.
What is the salary of Michael Weiser?
As the Independent Director of Iovance Biotherapeutics Inc, the total compensation of Michael Weiser at Iovance Biotherapeutics Inc is $708,375. There are 4 executives at Iovance Biotherapeutics Inc getting paid more, with Maria Fardis having the highest compensation of $4,107,960.
How old is Michael Weiser?
Michael Weiser is 57, he's been the Independent Director of Iovance Biotherapeutics Inc since 2018. There are 4 older and 11 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.
What's Michael Weiser's mailing address?
Michael's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS, CA, 94070.
Insiders trading at Iovance Biotherapeutics Inc
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak, eTimothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.
What does Iovance Biotherapeutics Inc do?
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
What does Iovance Biotherapeutics Inc's logo look like?
Complete history of Michael Weiser stock trades at Alaunos Therapeutics Inc e Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc executives and stock owners
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Maria Fardis,
President, Chief Executive Officer and Director -
Friedrich Graf Finckenstein,
Chief Medical Officer -
Frederick Vogt,
General Counsel, Corporate Secretary -
Iain Dukes,
Chairman of the Board -
Michael Weiser,
Independent Director -
Jean-Marc Bellemin M.B.A.,
Chief Financial Officer & Principal Accounting Officer -
Dr. Friedrich Graf Finckenstein M.D.,
Chief Medical Officer -
Dr. Frederick G. Vogt Esq., J.D., Ph.D.,
Interim Pres, CEO, Gen. Counsel & Corp. Sec. -
Merrill McPeak,
Independent Director -
Ryan Maynard,
Independent Director -
Athena Countouriotis,
Director -
Michael Swartzburg,
Interim Principal Financial Officer and Principal Accounting Officer -
Sara Pellegrino,
IR Contact Officer -
Wayne Rothbaum,
Independent Director -
Dr. Elma S. Hawkins,
Advisor to the Board -
Madan Jagasia,
Sr. VP of Medical Affairs -
James Ziegler,
Sr. VP of Commercial -
Howard B. Johnson,
Sr. VP of Corp. Devel., Alliance Management & Program Management -
Dr. Igor P. Bilinsky,
Chief Operating Officer -
Timothy E Morris,
Chief Financial Officer -
Jean Marc Bellemin,
Chief Financial Officer -
Igor Bilinsky,
Chief Operating Officer -
Wendy L Yarno,
Director -
Wendy L Dixon,
Director